Karin Jirström

Professor

Lund University
Country flag
Sweden

Research Interests

Explore related searches

Contact this professor

LinkedIn
ORCID
Google Scholar

About

Professor Karin Jirström is a faculty member at Lund University in Sweden. Her research encompasses various aspects of oncology, including tumor evolution and response in liver cancer, the clinical significance of insulin-like growth factor binding proteins in breast cancer, and the role of programmed death-ligand 1 in colorectal cancer prognosis. Additionally, she investigates the tumor microenvironment in triple-negative breast cancer and the impact of specific markers in gastric and esophageal adenocarcinomas.

Articles (22)

The Vitamin D Receptor as a Prognostic Marker in Breast Cancer—A Cohort Study

Previous research has indicated an association between the presence of the vitamin D receptor (VDR) in breast cancer tissue and a favorable prognosis. This study aimed to further evaluate the prognostic potential of VDR located in the nuclear membrane or nucleus (liganded). The VDR protein levels were analyzed using immunohistochemistry in tumor samples from 878 breast cancer patients from Lund, Sweden, included in the Breast Cancer and Blood Study (BCBlood) from October 2002 to June 2012. The follow-up for breast cancer events and overall survival was recorded until 30 June 2019. Univariable and multivariable survival analyses were conducted, both with complete case data and with missing data imputed using multiple imputation by chained equations (MICE). Tumor-specific positive nuclear membrane VDR(num) staining was associated with favorable tumor characteristics and a longer breast cancer free interval (BCFI; HR: 0.64; 95% CI: 0.44–0.95) and overall survival (OS; HR: 0.52; 95% CI: 0.34–0.78). Further analyses indicated that VDRnum status also was predictive of overall survival when investigated in relation to ER status. There were significant interactions between VDR and invasive tumor size (Pinteraction = 0.047), as well as mode of detection (Pinteraction = 0.049). VDRnum was associated with a longer BCFI in patients with larger tumors (HR: 0.36; 95% CI: 0.14–0.93) or clinically detected tumors (HR: 0.28; 95% CI: 0.09–0.83), while no association was found for smaller tumors and screening-detected tumors. Further studies are suggested to confirm our results and to evaluate whether VDR should and could be used as a prognostic and targetable marker in breast cancer diagnostics.

Year:

2024

Collaborators (23)

Johan Vallon-Christersson

Lund University

SWEDEN

Aidan Meade

Technological University Dublin

IRELAND

Hans Brunnström

Lund University

SWEDEN

Alfonso Martín-Bernabé

Karolinska Institutet

SWEDEN

Miklos Gulyas

MD, PhD, associate professor, senior consultant pathologist

Uppsala Universitet Medicinska fakulteten

SWEDEN

Johan Staaf

Lund University

SWEDEN

Signe Borgquist

Aarhus University

DENMARK

Konstantinos Papadakos

Lund University

SWEDEN

Jenny Karlsson

Lund University

SWEDEN

Subhayan Chattopadhyay

Lund University

SWEDEN

Helena Jernström

Lund University

SWEDEN

Mihaela Asp

Lund University

SWEDEN

Karin Leandersson

Lund University

SWEDEN

Johan Isaksson

Head of Department

-

SWEDEN

Thi Nguyet Que Nguyen

Technological University Dublin

IRELAND

Jutta Huvila

University of Turku

FINLAND

Carina Strell

Karolinska Institutet

SWEDEN

Caroline Bergenfelz

Lund University

SWEDEN

Anna Blom

Umeå Universitet Medicinska fakulteten

SWEDEN

Natalie Andersson

Lund University

SWEDEN

Christopher Godina

Lund University

SWEDEN

Anders Valind

Lund University

SWEDEN

Artur Mezheyeuski

Uppsala University

SWEDEN
Social connections

How do I reach out?

Sign in for free to see their profile details and contact information.

Meet Kite AI